Cardiovascular Disease Risk in a Cohort of Virologically Suppressed People Living with HIV Switching to Doravirine: Preliminary Data from the Real Life-Reference-Cited by-同舟云学术

Cardiovascular Disease Risk in a Cohort of Virologically Suppressed People Living with HIV Switching to Doravirine: Preliminary Data from the Real Life

Published:2022-11-01 Issue:11 Volume:38 Page:878-880
ISSN:0889-2229
Container-title:AIDS Research and Human Retroviruses
language:en
Short-container-title:AIDS Research and Human Retroviruses

Author:

Iannone Valentina¹,Farinacci Damiano¹^ORCID,D'Angelillo Anna¹,Dusina Alex²,Lamanna Francesco¹,Passerotto Rosanna¹,Baldin Gianmaria²^ORCID,Visconti Elena²,Tamburrini Enrica¹²,Borghetti Alberto²,Di Giambenedetto Simona¹²,Ciccullo Arturo³^ORCID

Affiliation:

1. Section of Infectious Diseases, Department of Safety and Bioethics, Catholic University of the Sacred Heart, Rome, Italy.

2. UOC Malattie Infettive, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.

3. Infectious Diseases Unit, San Salvatore Hospital, L'Aquila, Italy.

Publisher

Mary Ann Liebert Inc

Subject

Infectious Diseases,Virology,Immunology

Link

https://www.liebertpub.com/doi/pdf/10.1089/aid.2022.0050

Reference9 articles.

1. Doravirine: a new non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection